Skip to main content
SpringerLink
Log in

Understanding and Treating Dual Diagnosis: Double the Trouble

  • Published:
Current Addiction Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. SAMSHA. Key substance use and mental health indicators in the United States: results from the 2022 national survey on drug use and health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for behavioral health statistics and quality, substance abuse and mental health services administration. 2022.

  2. Efthimiou O, Taipale H, Radua J, Schneider-Thoma J, Pinzón-Espinosa J, Ortuño M et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet Psychiatry. 2024;11:102–11.

  3. Hjorthøj C, Østergaard ML, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, Nordentoft M. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. The Lancet Psychiatry. 2015;2:801–8.

  4. Chen LY, Crum RM, Martins S, Kaufmann CN, Strain EC, Mojtabai R. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv. 2013;64:863–70.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D. Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction. 2013;108(1):115–23.

    Article  PubMed  Google Scholar 

  6. Myran DT, Harrison LD, Pugliease M, Solmi M, Anderson KK, Fiedorowicz JG, et al. Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis. JAMA Psychiat. 2023;80:1169–74.

    Article  Google Scholar 

  7. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiat. 2015;72:1235–42.

    Article  Google Scholar 

  8. Hasin DS, Sarvet AL, Cerdá M, et al. US Adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. JAMA Psychiat. 2017;74:579–88.

    Article  Google Scholar 

  9. Hjorthøj C, Compton W, Starzer M, Nordholm D, Einstein E, Erlangsen A et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol Med. 2023;53:7322–8.

  10. Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force report: serotonergic psychedelic treatments for major depressive disorder. Can J Psychiatry. 2023;68:5–21.

    Article  PubMed  Google Scholar 

  11. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175:343–50.

    Article  PubMed  Google Scholar 

  12. Foulds JA, Lubman DI. Treating depression in patients with alcohol or drug use disorders: a need for clearer guidelines. Austral New Zealand J Psychiatry. 2017;51:668–9.

    Article  Google Scholar 

  13. Lucatch AM, Kloiber SM, Meyer JH, Rizvi SJ, George TP. Effects of extended cannabis abstinence in major depressive disorder. Can J Addiction. 2020;11:33–41.

    Article  Google Scholar 

  14. George TP, Welsh L, Franchuk SL, Vaccarino FJ. Why integrating medications and psychosocial interventions is important to successfully address the opioid crisis in Canada. Can J Psychiatry. 2022;67:176–8.

    Article  PubMed  Google Scholar 

  15. Gatov E, Rosella L, Chiu M, Kurdyak PA. Trends in standardized mortality among individuals with schizophrenia, 1993–2012: a population-based, repeated cross-sectional study. Can Med Assoc J. 2017;189:E1177–87.

    Article  Google Scholar 

  16. Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, DeMeo DL, Wells JM, Make BJ, Rennard SI, Washko GR. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax. 2018;73:414–21.

    Article  PubMed  Google Scholar 

  17. Kurdyak P, Vigod S, Calzavara A, Wodchis WP. High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia. Schizophr Res. 2012;142:52–7.

    Article  PubMed  Google Scholar 

  18. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.

    Article  CAS  PubMed  Google Scholar 

  19. Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, Savage C, Schweinfurth L, Stallings CR, Sweeney K, Yolken RH. Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv. 2018;69(2):147–53.

    Article  PubMed  Google Scholar 

  20. Mehta, D.D., Praecht, A., Ward, H.B., Sanches, M., Sorkhou, M., Tang, V.M., Steele, V.R., Hanlon, C.A., George, T.P. (2024). A systematic review and meta-analysis of neuromodulation therapies for substance use disorders. Neuropsychopharmacology, 2024; In Press.

  21. Dunlop K, Hanlon CA, Downar J. Noninvasive brain stimulation treatments for addiction and major depression. Ann NY Acad Sci. 2017;1394(1):31–54.

    Article  PubMed  Google Scholar 

  22. Tang VM, Le Foll B, Blumberger DM, Voineskos D. Repetitive transcranial magnetic stimulation for comorbid major depressive disorder and alcohol use disorder. Brain Sci. 2021;30(12):48.

    Article  Google Scholar 

Download references

Funding

This work was supported in part by a project grant (PJT-190053) from the Canadian Institutes of Health Research (CIHR) to Dr. George and a Brain and Behavior Research Foundation (BBRF) Young Investigator Award to Dr. Tang.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto; Institute of Mental Health Policy and Research, Centre for Addiction and Mental Health (CAMH), 60 White Squirrel Way, Room 312, Toronto, ON, M6J 1H4, Canada

    Victor M. Tang & Tony P. George

Authors
  1. Victor M. Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tony P. George
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

V.M.T. and T.P.G. wrote, reviewed, edited, and submitted the manuscript.

Corresponding author

Correspondence to Tony P. George.

Ethics declarations

Conflict of Interest

The Section Editors for the topical collection Dual Diagnosis are Tony George and Victor Tang. Please note that Section Editors Tony George and Victor Tang were not involved in the editorial process of this article as they are co-authors.

Human and Animal Rights and Informed Consent

No animal or human subjects were used by the authors for this Commentary.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, V.M., George, T.P. Understanding and Treating Dual Diagnosis: Double the Trouble. Curr Addict Rep (2024). https://doi.org/10.1007/s40429-024-00564-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40429-024-00564-0

Search

Navigation